- Home
- STEM vs QTTB Comparison
STEM vs QTTB Comparison
Compare STEM & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STEM | QTTB |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.3M | 80.0M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | STEM | QTTB |
|---|---|---|
| Price | $10.82 | $5.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $13.33 | $13.00 |
| AVG Volume (30 Days) | 90.9K | ★ 254.7K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | ★ $156,266,000.00 | $53,737,000.00 |
| Revenue This Year | $2.77 | N/A |
| Revenue Next Year | $14.65 | N/A |
| P/E Ratio | ★ N/A | $2.34 |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $0.35 | $1.40 |
| 52 Week High | $32.23 | $8.05 |
Technical Indicators
Market Signals| Indicator | STEM | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 41.18 |
| Support Level | $9.72 | $4.83 |
| Resistance Level | $10.99 | $7.69 |
| Average True Range (ATR) | 0.83 | 0.65 |
| MACD | 0.04 | -0.12 |
| Stochastic Oscillator | 37.00 | 10.98 |
Price Performance
Historical ComparisonAbout STEM Stem Inc.
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
About QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).